Anticoagulants oraux directs : dans quelles indications ? Lequel prescrire ? Pour ou contre chez les personnes fragiles et dans les situations atypiques ? Quelle surveillance et gestion des accidents hémorragiques ?

Kirchhof, 2016, 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Eur Heart J, 37, 2893, 10.1093/eurheartj/ehw210 January, 2019, J Am Coll Cardiol, 140, e125 Sanchez, 2019, Recommandations de bonne pratique pour la prise en charge de la maladie veineuse thromboembolique chez l’adulte – version longue, Rev Mal Respir, 36, 249, 10.1016/j.rmr.2019.01.003 Samama, 2011, Prévention de la maladie thromboembolique veineuse postopératoire. Actualisation 2011. Texte court, Ann Fr Anesth Réanimation, 30, 947, 10.1016/j.annfar.2011.10.008 Eriksson, 2007, Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the re-model randomised trial, J Thromb Haemost, 5, 2178, 10.1111/j.1538-7836.2007.02748.x Eriksson, 2007, Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial, Lancet, 370, 949, 10.1016/S0140-6736(07)61445-7 Ginsberg, 2009, Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery, J Arthroplasty, 24, 1, 10.1016/j.arth.2008.01.132 Lassen, 2008, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty, N Engl J Med, 358, 2776, 10.1056/NEJMoa076016 Turpie, 2009, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (record4): a randomised trial, Lancet, 373, 1673, 10.1016/S0140-6736(09)60734-0 Kakkar, 2008, Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial, Lancet, 372, 31, 10.1016/S0140-6736(08)60880-6 Eriksson, 2008, Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty, N Engl J Med, 358, 2765, 10.1056/NEJMoa0800374 Lassen, 2010, Apixaban versus enoxaparin for thromboprophylaxis after hip replacement, N Engl J Med, 363, 2487, 10.1056/NEJMoa1006885 Lassen, 2010, Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (advance-2): a randomised double-blind trial, Lancet, 375, 807, 10.1016/S0140-6736(09)62125-5 Lassen, 2009, Apixaban or enoxaparin for thromboprophylaxis after knee replacement, N Engl J Med, 361, 594, 10.1056/NEJMoa0810773 Buller, 2008, A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT dose-ranging study, Blood, 112, 2242, 10.1182/blood-2008-05-160143 The EINSTEIN investigators, 2012, Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, N Engl J Med, 366, 1287, 10.1056/NEJMoa1113572 Agnelli, 2013, Oral apixaban for the treatment of acute venous thromboembolism, N Engl J Med, 369, 799, 10.1056/NEJMoa1302507 van der, 2014, Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis, J Thromb Haemost, 12, 320, 10.1111/jth.12485 van, 2014, Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials, Blood, 124, 1968, 10.1182/blood-2014-04-571232 Gomez-Outes, 2014, Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review, Vasc Health Risk Manag, 10, 627, 10.2147/VHRM.S50543 Vedovati, 2014, Efficacy and safety of direct oral anticoagulants after pulmonary embolism: a meta-analysis, Int J Cardiol, 177, 601, 10.1016/j.ijcard.2014.08.136 Breddin, 2001, Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis, N Engl J Med, 344, 626, 10.1056/NEJM200103013440902 Rodger, 2008, Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy, CMAJ Can Med Assoc J, 179, 417, 10.1503/cmaj.080493 Weitz, 2017, Rivaroxaban or aspirin for extended treatment of venous thromboembolism, N Engl J Med, 376, 1211, 10.1056/NEJMoa1700518 Agnelli, 2013, Apixaban for extended treatment of venous thromboembolism, N Engl J Med, 368, 699, 10.1056/NEJMoa1207541 Ruff, 2014, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, Lancet, 383, 955, 10.1016/S0140-6736(13)62343-0 Delluc, 2016, Current incidence of venous thromboembolism and comparison with 1998: a community-based study in Western France, Thromb Haemost, 116, 967, 10.1160/TH16-03-0205 Kearon, 2016, Categorisation of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH, J Thromb Haemost, 14, 1480, 10.1111/jth.13336 Raskob, 2018, Edoxaban for the treatment of cancer-associated venous thromboembolism, N Engl J Med, 378, 615, 10.1056/NEJMoa1711948 Young, 2018, Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomised trial (SELECT-D), J Clin Oncol, 36, 2017, 10.1200/JCO.2018.78.8034 McBane, 2018, Apixaban, dalteparin, in active cancer associated venous thromboembolism, the ADAM VTE trial, Blood, 132, 421, 10.1182/blood-2018-99-118808 Carrier, 2019, Apixaban to prevent venous thromboembolism in patients with cancer, N Engl J Med, 380, 711, 10.1056/NEJMoa1814468 Khorana, 2019, Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer, N Engl J Med, 380, 720, 10.1056/NEJMoa1814630 Gerotziafas, 2017, A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS–cancer-associated thrombosis study, Oncologist, 22, 1222, 10.1634/theoncologist.2016-0414 Mega, 2012, Rivaroxaban in patients with a recent acute coronary syndrome, N Engl J Med, 366, 9, 10.1056/NEJMoa1112277 Eikelboom, 2017, Rivaroxaban with or without aspirin in stable cardiovascular disease, N Engl J Med, 377, 1319, 10.1056/NEJMoa1709118 Eikelboom, 2013, Dabigatran versus warfarin in patients with mechanical heart valves, N Engl J Med, 369, 1206, 10.1056/NEJMoa1300615 Renda, 2017, Non–vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease, J Am Coll Cardiol, 69, 1363, 10.1016/j.jacc.2016.12.038 Benhamou, 2019, Traitement du syndrome des antiphospholipides, place des anticoagulants oraux directs, JMV-J Médecine Vasc, 44, 120, 10.1016/j.jdmv.2018.12.065 Male, 2019, Abstract LB 01.5 Sharma, 2015, Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis, Circulation, 132, 194, 10.1161/CIRCULATIONAHA.114.013267 Sardar, 2014, New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomised trials, J Am Geriatr Soc, 62, 857, 10.1111/jgs.12799 Geldhof, 2014, Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants, Thromb J, 12, 21, 10.1186/1477-9560-12-21 De Caterina, 2017, The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight—a systematic literature review, Clin Res Cardiol, 106, 565, 10.1007/s00392-017-1102-5 McCaughan, 2018, Anticoagulation at the extremes of body weight: choices and dosing, Expert Rev Hematol, 11, 817, 10.1080/17474086.2018.1517040 Martin, 2016, Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH, J Thromb Haemost, 14, 1308, 10.1111/jth.13323 Tittl, 2018, Impact of BMI on clinical outcomes of NOAC therapy in daily care - results of the prospective dresden NOAC registry (NCT01588119), Int J Cardiol, 262, 85, 10.1016/j.ijcard.2018.03.060 Del-Carpio Munoz, 2016, Meta-analysis of renal function on the safety and efficacy of novel oral anticoagulants for atrial fibrillation, Am J Cardiol, 117, 69, 10.1016/j.amjcard.2015.09.046 Hoolwerf, 2018, Direct oral anticoagulants in patients with liver cirrhosis: a systematic review, Thromb Res, 170, 102, 10.1016/j.thromres.2018.08.011 Agence Nationale de Sécurité du Médicament et des produits de santé, 2014, 78 Steffel, 2018, The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation, Eur Heart J, 39, 1330, 10.1093/eurheartj/ehy136 Janczak, 2018, Rivaroxaban and apixaban for initial treatment of acute venous thromboembolism of atypical location, Mayo Clin Proc, 93, 40, 10.1016/j.mayocp.2017.10.007 Hanafy, 2019, Randomised controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis, Vascul Pharmacol, 113, 86, 10.1016/j.vph.2018.05.002 Ferro, 2017, European stroke organisation guideline for the diagnosis and treatment of cerebral venous thrombosis – endorsed by the European academy of neurology, Eur Stroke J, 2, 195, 10.1177/2396987317719364 Ferro, 2019, Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: a randomised clinical trial, JAMA Neurol, 76, 1457, 10.1001/jamaneurol.2019.2764 Cuker, 2014, Laboratory measurement of the anticoagulant activity of the non–vitamin K oral anticoagulants, J Am Coll Cardiol, 64, 1128, 10.1016/j.jacc.2014.05.065 Reilly, 2014, The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (randomised evaluation of long-term anticoagulation therapy), J Am Coll Cardiol, 63, 321, 10.1016/j.jacc.2013.07.104 Albaladejo, 2018, Management of bleeding and emergency invasive procedures in patients on dabigatran: updated guidelines from the French working group on perioperative haemostasis (GIHP) – september 2016, Anaesth Crit Care Pain Med, 37, 391, 10.1016/j.accpm.2018.04.009 Monelli, 2019, Non-vitamin K oral anticoagulant use in the elderly: a prospective real-world study – data from the registry of patients on non-vitamin K oral anticoagulants (REGINA), Vasc Health Risk Manag, 15, 19, 10.2147/VHRM.S191208 Tromeur, 2018, Novel anticoagulant treatment for pulmonary embolism with direct oral anticoagulants phase 3 trials and clinical practice, Semin Interv Radiol, 35, 83, 10.1055/s-0038-1642622